Amgen Inc.
Price
Overview
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Leadership
{"bio":"As Chief Executive Officer of Amgen Inc., Robert A. Bradway leads one of the world's premier biotechnology companies. Amgen is dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need, using sophisticated human genetics and biology insights to bring forward therapies that can make a difference in patients' lives. Amgen's work spans a range of serious illnesses, including cardiovascular disease, kidney disease, cancer, bone disease, and inflammatory conditions. Their approach involves a deep understanding of the underlying biological mechanisms driving these diseases, aiming to create treatments that address the root causes rather than just the symptoms. The company's commitment extends from early-stage research and discovery all the way through to the commercialization of medicines, ensuring that advancements reach the patients who need them."} {"bio":"Before assuming leadership at Amgen, Bradway held a variety of significant roles within the biopharmaceutical sector. Earlier in his career, he served in roles that provided him with broad experience in both operations and strategy within the healthcare industry. His tenure at Amgen began with executive responsibilities, including the position of Chief Operating Officer, where he played a key part in the company's operational execution and strategic planning. This background provided him with a comprehensive understanding of the company's diverse functions and the broader pharmaceutical landscape, preparing him for the chief executive role. His career path reflects a consistent involvement in advancing the development and delivery of new medicines."} {"bio":"Under Bradway's leadership, Amgen has continued to emphasize a science-driven strategy, focusing on leveraging deep biological understanding and human genetics to identify and develop novel therapies. A notable strategic priority has been the expansion into new therapeutic areas and the advancement of a robust pipeline, including investments in areas like oncology and inflammation. He has also overseen efforts to enhance manufacturing capabilities and embrace new technologies to improve efficiency and patient access. Today, Amgen is recognized as a significant player in the biotechnology industry, known for its scientific rigor and its commitment to addressing challenging diseases. The company maintains a strong position, characterized by its established portfolio of medicines and its ongoing pursuit of scientific breakthroughs for significant unmet medical needs."}
History & business model
This section is waiting to be written.
InvestWiki is community-edited. Contribute a plain-English history of Amgen Inc., its business model, key products, and controversies.